This blog explores the role of BCL6 as a central lymphoma driver and the clinical progress of Bristol Myers Squibb’s oral degrader BMS-986458. It also discusses AI-driven retrosynthesis tools like ChemAIRS, which propose palladium-free, scalable synthetic routes to overcome key challenges in PROTAC development.